Platelet Concentrate Preparation
Platelet Concentrate Preparation - Related Videos
02:40
Preparation of Platelet-Rich Plasma from Human Peripheral Blood
0 Views •
2026
Source:Sathish Muthu1,2,31Orthopaedic Research Group, Coimbatore.2Department of Biotechnology, Faculty of Engineering, Karpagam Academy of Higher Education.3Department of Orthopaedics, Government Medical College.This video demonstrates the preparation of high-quality Platelet-Rich Plasma (PRP) by screening for platelet count, collecting and centrifuging blood, and isolating platelets. This PRP is used in therapeutic applications for tissue regeneration and healing.
12:40
Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
0 Views •
Cited by 4 •
2012
This article describes the process used by Örebro University Hospital to produce double dose buffy coat platelet concentrates prepared from whole blood donations and treated with the INTERCEPT Blood System for pathogen inactivation. The in vitro quality of the final platelet units are evaluated over 7 days of storage.
09:13
Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
0 Views •
Cited by 5 •
2017
We describe a straightforward method for the isolation of washed platelets from human blood followed by agonist-induced platelet aggregation measurements by turbidimetry. As an example we apply this method for studying the aggregation response of human platelets to collagen after a pre-incubation with the Pannexin1 channel inhibitor Brilliant Blue FCF.
08:32
Preparation of Pooled Human Platelet Lysate (pHPL) as an Efficient Supplement for Animal Serum-Free Human Stem Cell Cultures
0 Views •
Cited by 133 •
2009
Human platelet lysate is a rich source of growth factors and a potent supplement in cell culture. This protocol presents the process of preparing a large pool of human platelet lysate by starting from platelet rich plasma, performing several freeze-thaw cycles and depleting the platelet fragments.
09:38
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
0 Views •
Cited by 13 •
2017
This paper describes an experimental model of hemostasis that simultaneously measures platelet function and coagulation. Platelet and fibrin fluorescence is measured in real-time, and platelet adhesion rate, coagulation rate, and onset of coagulation are determined. The model is used to determine platelet procoagulant properties under flow in concentrates for transfusion.
FAQs
Controlled centrifugation separates the platelet-rich fraction from anticoagulated whole blood while limiting conditions that could compromise platelet quality. The goal is to collect platelets in a form that retains viability and function, rather than simply dividing the donation into components. This separation step therefore directly affects the suitability of the resulting concentrate for transfusion.
Anticoagulated blood provides the starting material for separating a platelet-rich fraction while preserving the intended collection conditions. During platelet concentrate preparation, that controlled starting state supports centrifugation or automated cell separation. It also creates a consistent basis for assessing the collected product before storage and determining its clinical suitability.
Platelets must remain viable and functional after separation because the concentrate is intended to support hemostasis when transfused. Storage conditions are therefore part of the preparation process, not an afterthought. Quality control checks these conditions alongside platelet content and sterility, helping determine whether the product remains suitable for clinical use.
The workflow proceeds from collecting anticoagulated blood or an apheresis donation to isolating the platelet-rich fraction through controlled centrifugation or automated cell separation. The collected product is then stored under conditions intended to preserve viability and function. Before administration, quality control evaluates key product characteristics, supporting a decision about clinical suitability.
Assessment focuses on platelet content, sterility, storage conditions, and overall clinical suitability. These checks examine both what has been collected and how it has been maintained. Together, they provide a standardized basis for deciding whether the concentrate can be used safely and appropriately for a patient who needs support for hemostasis.
Clinicians may administer the product to reduce bleeding risk before a procedure or to address active bleeding. Its role is especially relevant when thrombocytopenia or impaired platelet function compromises hemostasis. Because preparation and quality control establish the product's suitability, transfusion decisions can be aligned with the patient's clinical need rather than relying on a single standard use.